Triple meeting 2024 – Tyra’s targeted FGFR3 push
The company reckons it’s got what it takes to hit the right member of the FGFR family.
Not so B-Fast for Roche
The focus for divarasib in second-line lung is now the head-to-head Krascendo-1 trial.
AstraZeneca shores up its Tagrisso defences
The Hutchmed-originated savolitinib moves towards its first US approval.
Triple meeting 2024 – can Revolution succeed where others stumbled?
The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.
Ipsen casts doubt on Pfizer’s prostate plan
Mevrometostat is the only EZH2 inhibitor in phase 3 for prostate cancer.
